Introduction {#s1}
============

It is well established that individual patients can have significantly different responses to clinical drugs. Drug concentration in plasma can vary \~600-fold between two individuals of the same weight who have received the same drug dosage, and this can result in non-efficiency or adverse drug reactions (ADRs) \[[@B1]\]. ADR ranks as the 5th leading cause of death and illness in the developed world, imposing costs estimated at 100 billion USD in the US and causing over 100,000 deaths every year \[[@B2],[@B3]\]. Because of its large population and poor medical conditions, the problem of ADR fatality is even more serious in China. A report by the WHO estimated that 2.5 million Chinese patients are hospitalized annually due to ADR, of whom 190,000 lose their lives \[[@B4]\]. Within the pathway of drug response, it is well known that the cytochrome P450 (*CYP*) superfamily plays a critical role in metabolic biotransformation, mediating up to 90% of all drug oxidation metabolism \[[@B5]\]. Five major *CYP* genes---*CYP2E1*, *CYP2D6*, *CYP2C9* ,*CYP2C19* and *CYP3A4/5* play the most important role in drug metabolism, respectively accounting for 4%, 19%, 16%, 8% and 34% of the metabolizing process \[[@B6]\]. Different enzymes within the *CYP* family metabolize different drugs and many drugs are metabolized by a combination of *CYP*s.

Individual variability in drug response can be attributable to factors such as age, gender, or environmental factors but genetic differences in particular, can account for 15%--30% ,or even higher in some groups, of inter-individual differences in drug metabolism and response \[[@B1]\]. Polymorphisms of the *CYP* enzymes have been widely identified, with two or more variant alleles. These variants in the DNA sequence of genes, to some extent, decrease, increase or completely abolish the enzyme activity. Individuals can be classified as extensive metabolizers (EM or wild type), poor metabolizers (PM), intermediate metabolizers (IM) and ultrarapid metabolizers (UM) according to their ability to metabolize drug substrates.

The enzyme activity variability of *CYP* genes attributable to genetic factors can be used as a predictor for individualized therapy to improve clinical efficacy or avoid ADR. The relationship between specific *CYP* enzyme activity and its gene polymorphism has been widely studied (<http://www.CYPalleles.ki.se/>). It has been shown that allele frequencies vary largely between different populations and geographic areas and a number of pharmacogenomics studies have investigated different drug metabolism genes in specific geographic areas and ethnic groups. Our own group has also conducted a gene polymorphism analysis of different *CYP* genes in the Chinese population \[[@B7]--[@B10]\]. However, most of these studies have focused on single genes \[[@B11]\], drug metabolism usually involves multiple *CYP* genes. Multi-gene analysis is therefore important in drug response evaluation but, to date, no systematic combined genotype and functional combinations analysis of multiple *CYP* genes in different geographic areas for the same population has been undertaken. In the present study, we focused on analyzing the functional combinations of four major *CYP* genes---*CYP2E1*, *CYP2D6*, *CYP2C9* and *CYP2C19* genes in different geographic areas in within the Chinese Han population. *CYP*3A4/5 was not among the genes studied since its enzyme variation is associated more with non-genetic factors than directly with genetic factors. Our work is the first to apply a systemic combined analysis to the field of personalized drug provision and could provide a useful basis for clinical genotype testing.

Materials and Methods {#s2}
=====================

Subjects {#s2.1}
--------

The samples for the study were collected from 400 healthy unrelated volunteers living in four different areas of the Chinese mainland. 100 subjects from Xi'an City, which lies in the west of China; 100 subjects from Shanghai City, which lies in the east of China; 100 subjects from Shenyang City, which lies in the north of China; and 100 subjects from Shantou City, which lies in the south of China. Each group of 100 subjects consisted of 50 males and 50 females between 18 and 53 years of age. All subjects were judged to be in good health in terms of their medical history and after a physical examination. All the volunteers in this study were of homogenous Chinese Han ethnicity. The study was approved by the Shanghai Ethical Committee of Human Genetic Resources and all subjects gave informed consent for their participation.

Polymerase chain reaction condition and DNA sequencing {#s2.2}
------------------------------------------------------

Systematic polymorphism screening had been performed using long-PCRs and direct sequencing in some of our previous work. Genomic DNA was isolated from peripheral blood using standard procedures \[[@B12]\]. PCR primers were designed to amplify 2000 bp of the 5´-flanking regions and all exons of the *CYP* gene. In case any sequence was missed, overlapping primers were used. The PCRs were carried out on the Gene Amp® PCR system 9700 (Applied Biosystems, CA, USA). The amplification mixture contained a final volume of 25µl: 10 ng of genomic DNA, 10 mM Tris-HCl (pH8.3), 50 mM KCl, 1.5--3.0 mM MgCl2, 200 mM dNTP, 1 mM of each primer and 0.25 U Taq DNA polymerase. The amplification conditions were: 95°C for 1 min, followed by 30--35 cycles at 95°C for 30 s, 50--65°C for 1 min, 72°C for 1 min, then a final extension at 72°C for 10 min. Preparation of DNA for sequencing included incubation of PCR products with 0.1 U of shrimp alkaline phosphatase (Roche, Basel, Switzerland) and 0.5 U of exonulease I (New England Biolabs Inc., MA, USA) at 37°C for 45 min, followed by heat inactivation at 85°C for 20 min. The PCR products were sequenced using an ABI Prism® BigDye Terminator Cycle Sequencing Kit, version 3.1 (Applied Biosystems) on an ABI Prism 3730 sequencer.

Combined genotype analysis {#s2.3}
--------------------------

The analysis of allele and genotype frequencies of *CYP2E1*, *CYP2D6*, *CYP2C9*, and *CYP2C19* in the Chinese Han population had been performed in one of our earlier studies. Genotypes of the four genes were reviewed again for each sample and rearranged as necessary for the current investigation ([[http://www.CYPalleles.ki.se/]{.ul}](http://www.cypalleles.ki.se/)). On the basis of each sample data, a combined genotype analysis ([Table 1](#pone-0071934-t001){ref-type="table"}) was performed, calculating the combination frequency of the four CYP genes found in the sample. The comparison of combined genotype frequencies among different geographic of chinese have been done usingχ^2^ tests with a significant level set at 0.05.

10.1371/journal.pone.0071934.t001

###### The combined genotype frequency in four different geographical Chinese populations.

  **Combined genotype**   **Combined genotype frequency**                                                               
  ----------------------- --------------------------------- --------- --------- ------- ------- ------- ------- ------- -------
  \*1/\*1                 \*1/\*1                           \*1/\*1   \*1/\*1   3.13%   5.21%   0       1.04%   2.34%   0.264
  \*1/\*1                 \*1/\*1                           \*1/\*1   \*1/\*2   3.13%   1.04%   3.13%   0       1.82%   0.059
  \*1/\*1                 \*1/\*10                          \*1/\*1   \*1/\*1   4.17%   7.29%   9.38%   5.21%   6.51%   0.501
  \*1/\*1                 \*1/\*10                          \*1/\*1   \*1/\*2   2.08%   2.08%   2.08%   3.13%   2.34%   0.317
  \*1/\*1                 \*1/\*10                          \*1/\*3   \*1/\*1   4.17%   0       0       0       1.04%   0.79
  \*1/\*1                 \*1/\*2                           \*1/\*1   \*1/\*1   1.04%   2.08%   1.04%   0       1.04%   0.18
  \*1/\*1                 \*10/\*10                         \*1/\*1   \*1/\*1   2.08%   4.17%   5.21%   4.17%   3.91%   0.165
  \*1/\*1                 \*10/\*10                         \*1/\*1   \*1/\*2   2.08%   2.08%   1.04%   7.29%   3.13%   0.105
  \*1/\*1                 \*10/\*10                         \*1/\*1   \*2/\*2   2.08%   2.08%   0       1.04%   1.30%   0.18
  \*1/\*1                 \*2/\*10                          \*1/\*1   \*1/\*1   1.04%   1.04%   2.08%   0       1.04%   0.819
  \*1/\*7                 \*1/\*1                           \*1/\*1   \*1/\*1   1.04%   0       3.13%   5.21%   2.34%   0.264
  \*1/\*7                 \*1/\*1                           \*1/\*1   \*1/\*2   0       3.13%   0       3.13%   1.56%   0.434
  \*1/\*7                 \*1/\*10                          \*1/\*1   \*1/\*1   0       2.08%   5.21%   2.08%   2.34%   0.739
  \*1/\*7                 \*1/\*10                          \*1/\*1   \*1/\*2   1.04%   4.17%   2.08%   0       1.82%   0.368
  \*1/\*7                 \*10/\*41                         \*1/\*1   \*1/\*1   3.13%   0       1.04%   0       1.04%   0.317
  \*1/\*7                 \*10/\*10                         \*1/\*1   \*1/\*1   1.04%   1.04%   4.17%   5.21%   2.86%   0.529
  \*1/\*7                 \*10/\*10                         \*1/\*1   \*1/\*2   0       3.13%   0       1.04%   1.04%   0.317
  \*5/\*7                 \*1/\*1                           \*1/\*1   \*1/\*1   3.13%   0       1.04%   1.04%   1.30%   0.655
  \*5/\*7                 \*1/\*10                          \*1/\*1   \*1/\*1   4.17%   2.08%   5.21%   4.17%   3.91%   0.165
  \*5/\*7                 \*1/\*10                          \*1/\*1   \*1/\*2   3.13%   3.13%   1.04%   1.04%   2.08%   0.157
  \*5/\*7                 \*10/\*10                         \*1/\*1   \*1/\*1   1.04%   1.04%   3.13%   4.17%   2.34%   0.717
  \*5/\*7                 \*10/\*10                         \*1/\*1   \*1/\*2   3.13%   1.04%   0       3.13%   1.82%   0.059
  \*7/\*7                 \*1/\*10                          \*1/\*1   \*1/\*1   1.04%   1.04%   2.08%   2.08%   1.56%   0.414
  \*7/\*7                 \*10/\*10                         \*1/\*1   \*1/\*1   1.04%   2.08%   2.08%   2.08%   1.82%   0.059
  \*7/\*7                 \*10/\*10                         \*1/\*1   \*1/\*2   1.04%   0       0       3.13%   1.04%   0.317

a The P value is for the comparison of the combined genotype frequencies among the fourdifferent geographic populations

Functional combinations analysis {#s2.4}
--------------------------------

Our previous studies had established the predicted metabolic phenotypes (EM, IM, PM, UM) of the four CYP genes in different geographic areas based on genotype results for each sample. Individuals with two alleles coding for "normal" enzyme function were termed EM, whereas those with two variant alleles resulting in an inactive or absent enzyme were termed PM \[[@B13]\]. If one of alleles was normal but another resulted in reduced enzyme activity, it was regarded as IM. In some rare cases, such as for the *CYP2D6* gene in some populations, gene duplication and multiplication can lead to UM. A functional combinations analysis of the four CYP genes was completed by aggregating each sample's combined metabolic phenotypes and calculating the functional combinations frequency for the overall population. The comparison of functional combinations frequencies among different geographic of chinese have been done usingχ^2^ tests with a significant level set at 0.05. All tastics were been implemented on SPSS 17.0 platform.

Pharmacogenomics Associations analysis {#s2.5}
--------------------------------------

The well-known pharmacogenomics associations have been summarized, including four CYP genes used in this study and other genes and polymorphisms related to drug response drawn from various websites ([[http://www.pharmgkb.org/search/knownPairs.action]{.ul}](http://www.pharmgkb.org/search/knownPairs.action); [[http://stitch.embl.de/]{.ul}](http://stitch.embl.de/))

Results {#s3}
=======

The genotype analysis detected a total of 167 genotype combinations ([Table S1](#pone.0071934.s001){ref-type="supplementary-material"}) of the four genes in the sample of 400 Chinese Han subjects. Most of these combinations appeared in less than 1% of all samples. 25 combinations with frequencies greater than 1% were used as a focus group, making up 53.39% of all samples ([Table 1](#pone-0071934-t001){ref-type="table"}). The genotype of *CYP2C9* plays a small part in the focus group, featuring almost entirely as wild type \*1/\*1 with only one as type \*1/\*3. The most common 3 allele combinations (the unified order for combinations referred to later in this article) are (*CYP2E1*-*CYP2D6*-*CYP2C9*-*CYP2C19*) (\*1/1, \*1/\*10, \*1/\*1, \*1/\*1), (\*1/1, \*10/\*10, \*1/\*1, \*1/\*1), (\*5/7, \*1/\*10, \*1/\*1, \*1/\*1), respectively, and these appear in 6.51%, 3.91% and 3.91% of the Chinese population. Of the 25 genotype combinations, 11 exceeded a 2% frequency in the population, accounting for a 34.11% frequency overall. None of the combinations exhibit the obvious differences between four geographic areas in chinese (P value\>0.05).

On the basis of previous genotype analyses, we identified all the metabolic phenotypes for the four CYP genes in the four areas and in China as a whole ([Table 2](#pone-0071934-t002){ref-type="table"}). The EM for *CYP2D6* (60.42%) and *CYP2C19* (53.39%) is significantly lower than for *CYP2E1* (93.49%) and *CYP2C9* (88.02%) in the Chinese Han population. The distribution of intermediate metabolizer phenotypes for *CYP2D6* and *CYP2C19* together account for more than 30%, in contrast to *CYP2E1* (2.60%) and *CYP2C9* (9.11%). The ultrarapid metabolizer (UM) phenotype did not feature for *CYP2E1* and *CYP2C9*, and displayed only low frequencies for *CYP2D6* (0.78%) and *CYP2C19* (1.30%). Comparing the incidence of poor metabolizers (PM) among the four CYP phenotype frequencies, *CYP2C19* registered at 11.20% compared with fewer than 4% for all the others. The differences between four geographic areas were clear for PM of *CYP2E1*, IM of CYP2C9 and CYP2C19, EM of *CYP2C19*(P value\<0.05).

10.1371/journal.pone.0071934.t002

###### The phenotype frequency in four different geographical Chinese populations.

                                   **Metabolic phenotype frequency**                                       
  -------------------------------- ----------------------------------- -------- -------- -------- -------- -------
  (**U**)ultrarapid metabolizer    0                                   0        0        0        0        /
  (**E**)Extensitive metabolizer   86.46%                              96.88%   97.92%   92.71%   93.49%   0.813
  (**I**)Inermediate metabolizer   4.17%                               1.04%    1.04%    4.17%    2.60%    0.058
  (**P**)Poor metabolizer          9.38%                               2.08%    1.04%    3.13%    3.91%    0.016
  **CYP 2D6 phenotype**                                                                                    
  (**U**)ultrarapid metabolizer    1.04%                               0        1.04%    1.04%    0.78%    0.655
  (**E**)Extensitive metabolizer   66.67%                              61.46%   63.54%   50.00%   60.42%   0.436
  (**I**)Inermediate metabolizer   32.29%                              37.50%   35.42%   47.92%   38.28%   0.286
  (**P**)Poor metabolizer          0                                   1.04%    0        1.04%    0.52%    0.343
  **CYP 2C9 phenotype**                                                                                    
  (**U**)ultrarapid metabolizer    0                                   0        0        0        0        /
  (**E**)Extensitive metabolizer   83.33%                              92.71%   79.17%   96.88%   88.02%   0.492
  (**I**)Inermediate metabolizer   14.58%                              5.21%    14.58%   2.08%    9.11%    0.001
  (**P**)Poor metabolizer          2.08%                               2.08%    1.04%    0        1.30%    0.18
  **CYP 2C19 phenotype**                                                                                   
  (**U**)ultrarapid metabolizer    0                                   1.04%    2.08%    2.08%    1.30%    0.18
  (**E**)Extensitive metabolizer   44.79%                              43.75%   72.92%   52.08%   53.39%   0.017
  (**I**)Inermediate metabolizer   38.54%                              39.58%   17.71%   36.46%   33.07%   0.022
  (**P**)Poor metabolizer          15.63%                              14.58%   6.25%    8.33%    11.20%   0.084

b The P value is for the comparison of the metabolic phenotype frequencies among the fourdifferent geographic populations.

By integrating the results of combined genotype analysis and metabolic phenotype predictions, we combined the metabolic phenotypes of four genes and analyzed the functional combinations frequency in the four geographical areas of China. We choose 25 functional combinations which included more than two non-wild types (UM, IM, PM) of the four genes ([Table 3](#pone-0071934-t003){ref-type="table"}). All these groups were classified into 9 types, 6 containing two non-wild phenotypes (such as IM-IM-EM-EM) and the remaining combinations containing three non-EM phenotypes (such as PM-IM-EM-PM). Four functional combinations were identified as having greater than 1% frequency in the Chinese population. The two most important of these consist of non-EMs of both *CYP2D6* and *CYP2C19*, accounting for 10.94% (EM-IM-EM-IM) and 4.69% (EM-IM-EM-PM) respectively. For the majority of polymorphisms of *CYP2D6* and its functional variations which are obviously greater than other three genes, the frequency of non-wild combinations with *CYP2C9* (16.93%) and *CYP2C19* (2.86%) are higher compared with other combination which have a frequency of less than 2%. Only one type of combination (EM-IM-EM-IM) shows obvious differences betweeen four geographic areas(P value\<0.01).

10.1371/journal.pone.0071934.t003

###### The functional combinations frequency of four *CYP* genes in four different geographical populations.

  **Functional combinations**                                           **Functional combinations frequency**                                                                
  --------------------------------------------------------------------- --------------------------------------- -------- ------- -------- -------- ------- -------- -------- -------
  IM                                                                    IM                                      EM       EM      0        0        1.04%   1.04%    0.52%    0.825
  PM                                                                    IM                                      EM       EM      0        0        0       2.08%    0.52%    0.652
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2E1 & CYP2D6             0                                       0        1.04%   3.12%    1.04%    0.317                     
  IM                                                                    EM                                      PM       EM      0        1.04%    0       0        0.26%    0.716
  PM                                                                    EM                                      IM       EM      1.04%    0        0       0        0.26%    0.645
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2E1 & CYP2C9             1.04%                                   1.04%    0       0        0.52%    0.825                     
  IM                                                                    EM                                      EM       IM      1.04%    0        0       0        0.26%    0.745
  PM                                                                    EM                                      EM       IM      2.08%    1.04%    0       0        0.78%    0.654
  PM                                                                    EM                                      EM       PM      3.12%    0        0       1.04%    0.26%    0.463
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2E1 & CYP2C19            4.16%                                   1.04%    0       1.04%    0.43%    0.414                     
  EM                                                                    IM                                      IM       EM      2.08%    1.04%    5.21%   1.04%    2.34%    0.368
  EM                                                                    IM                                      PM       EM      0        1.04%    1.04%   0        0.52%    0.364
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2D6 & CYP2C9             2.08%                                   2.08%    6.25%   1.04%    2.86%    0.178                     
  EM                                                                    IM                                      EM       IM      12.50%   9.38%    3.13%   18.75%   10.94%   0.006
  EM                                                                    IM                                      EM       PM      8.33%    5.21%    0       5.21%    4.69%    0.637
  EM                                                                    IM                                      EM       UM      1.04%    1.04%    0       1.04%    0.52%    0.541
  EM                                                                    PM                                      EM       IM      0        0        0       1.04%    0.26%    0.642
  EM                                                                    UM                                      EM       IM      0        0        0       1.04%    0.52%    0.476
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2D6 & CYP2C19            9.37%                                   15.63%   3.13%   27.08%   16.93%   0.001                     
  EM                                                                    EM                                      IM       IM      1.04%    1.04%    2.08%   0        1.04%    0.522
  EM                                                                    EM                                      IM       PM      0        1.04%    0       0        0.26%    0.742
  EM                                                                    EM                                      PM       IM      2.08%    0        0       0        0.52%    0.655
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2C9 & CYP2C19            3.12%                                   2.08%    2.08%   0        1.82%    0.714                     
  EM                                                                    IM                                      IM       IM      1.04%    0        0       0        0.26%    0.754
  EM                                                                    IM                                      IM       PM      1.04%    0        0       0        0.26%    0.623
  EM                                                                    IM                                      IM       UM      0        0        1.04%   0        0.26%    0.844
  EM                                                                    UM                                      IM       IM      0        0        1.04%   0        0.26%    0.423
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2D6 & CYP2C9 & CYP2C19   2.08%                                   0        2.08%   0        1.04%    0.765                     
  IM                                                                    EM                                      IM       IM      1.04%    0        0       0        0.26%    0.645
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2E1 & CYP2C9 & CYP2C19   1.04%                                   0        0       0        0.26%    0.645                     
  IM                                                                    IM                                      EM       PM      1.04%    0        0       1.04%    0.52%    0.324
  PM                                                                    IM                                      EM       IM      2.08%    1.04%    0       0        0.78%    0.564
  PM                                                                    IM                                      EM       PM      1.04%    0        1.04%   0        0.52%    0.825
  Total[\*](#ngtab3.2){ref-type="table-fn"} CYP2E1 & CYP2D6 & CYP2C19   4.16%                                   1.04%    1.04%   1.04%    1.82%    0.705                     

c The P value is for the comparison of the functional combinations frequencies among the fourdifferent geographic populations

Total *CYP* stands for non-EM (wild) phenotype in combination

In order to demonstrate the importance of combined genotype and functional combinations analysis, we investigated previous research into well-known pharmacogenomics association between drugs and genes and details of several drugs that are metabolized by more than one CYP genes ([Table 4](#pone-0071934-t004){ref-type="table"}). We also used bioinformatics (STICH 3.1) analysis to investigate the concrete relationship between drugs and drug response related genes. For instance we used this method to investigate the drug response related genes for the antidepressant---fluvoxamine and the results are shown in [Figure 1](#pone-0071934-g001){ref-type="fig"}. This drug has complex associations with 7 metabolizing genes and 3 other related genes.

10.1371/journal.pone.0071934.t004

###### Relationships between drugs and drug related genes.

  **Drug**        **Drug related genes**                          **Drug function**
  --------------- ----------------------------------------------- ---------------------------
  Citalopram      *CYP2D6* , *CYP2C19*                            Antidepressant medication
  Fluvoxamine     CYP1A2, *CYP2C19*, *CYP2C9*, *CYP2D6*, CYP3A4   Antidepressant medication
  Imipramine      *CYP2D6*, *CYP2C19*                             Antidepressant medication
  Clopidogrel     *CYP2C19*, CYP3A4                               Antiplatelet agent
  Chlorzoxazone   *CYP2E1*, CYP1A2                                Muscle relaxant
  Modafinil       *CYP2D6*, *CYP2C19*, *CYP2C9*                   Stimulant-like drug
  Nelfinavir      *CYP2C19*, CYP3A                                Antiretroviral drug
  Phenprocoumon   *CYP2C9*, VKORC1                                Antiretroviral drug
  Warfarin        *CYP2C9*, VKORC1                                Anticoagulant

![Drug-gene relationship network centered on fluvoxamine.](pone.0071934.g001){#pone-0071934-g001}

Discussion {#s4}
==========

Pharmacogenetics has been seen as having great promise for individualized therapy. Several studies have demonstrated that genotype testing has the potential to optimize personalized medicine use \[[@B14],[@B15]\]. *CYP450* is the major enzyme involved in drug metabolism, accounting for about 75% of the total process \[[@B16]\]. Pharmacogenetics tests for *CYP450* genotypes have been developed and granted by FDA \[[@B17]\]. However, the current studies and commercial tests are mainly limited to the effects of single gene polymorphisms, despite the fact that most drugs metabolism exhibits poly-genetic traits. Our study is the first to investigate the combined genotypes and functional combinations of four main *CYP* genes in the Chinese population and could provide a theoretical basis for systematically evaluating drug efficacy in the context of personalized medicine.

The 167 genotype combinations discovered in our study provide a complete profile of the genotype variations of the main *CYP* genes in the Chinese Han population. Among the 25 principal genotype combinations based on the genotype of *CYP2C9*, almost all displayed the wild type \*1/\*1 with only one displaying type \*1/\*3, which would suggest that *CYP2C9* is particularly common in the Chinese population. Though we concentrated on genotype combinations with an incidence of more than 1%, given the large size and wide distribution of the Chinese Han population, rare combinations could also play a significant role in individual drug response. The geographical variations in genotype combinations which we observed, may not be permanent as living environments and lifestyles change over time within regions and within sub-groups of the population. However, variation in regional results may also be due to our relatively small-size samples, and the results would need to be confirmed by larger-size samples.

The metabolic phenotype analysis of the four main *CYP* genes revealed significant distributional differences of the four CYP genes across the population. Our results identified 11.2% poor metabolizers for *CYP2C19*, which is consistent with a previous report showing a frequency of 13.7% in the Chinese population \[[@B18]\]. Phenotype distribution differences across the four geographical areas were identified in our study, as, for example the EM and PM of *CYP2C19* for four geographic areas are significantly different(P value \<0.05). Phenotype differences attributable to geographical or population variation have been identified around the world, such as the frequency of poor metabolizers for *CYP2D6* which is approximately 3-10% in Caucasians, 1--2% in Orientals and 1.9% among Afro Americans \[[@B19],[@B20]\]. Our metabolic phenotype analysis effectively complements this data in terms of the Chinese Han population. Our analysis is the first to study functional combinations in four areas of the Chinese Han population, and should provide a useful reference point for effective clinical medication. As shown in [Table 4](#pone-0071934-t004){ref-type="table"}, the metabolism of most drugs is always related to more than one CYP enzyme. Such as antidepressant---fluvoxamine, metabolized by both CYP2D6, CYP2C9 and CYP2C19, only one type CYP genotype analysis is not enough as genetic evidence in clinical. In addition, effective therapy for most complex diseases generally needs combined therapy rather than a mono-drug approach, involving more than one kind of drug response pathway. Furthermore, as shown in [Figure 1](#pone-0071934-g001){ref-type="fig"}, drug response can often be related to more complex gene relationships. Systemic functional combinations analysis will therefore become increasingly important for a precise evaluation of drug response. According to our results, the two functional combinations with the highest frequencies (10.94% and 4.69%) involve non-EMs of *CYP2D6* and *CYP2C19*, and this data could be useful for drug response evaluation for the many antidepressant drugs metabolized by these two genes as listed in [Table 4](#pone-0071934-t004){ref-type="table"}.

In conclusion, in the present study we conducted a systematically combined genotype and functional combination analysis of four CYP genes in four different geographic areas of mainland China. Data on the profiles of the combined alleles and functional combinations of the four main *CYP* genes could provide a foundation for a systematic pharmacogenomics evaluation of drug efficacy in the context of individualized therapy.
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